跳至主要内容
临床试验/NCT06575049
NCT06575049尚未招募不适用

Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients

Seoul National University Hospital0 个研究点目标入组 60 人开始时间: 2025年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
60
主要终点
Postoperative hemovac or JP total drainage amount

研究概览

简要总结

We aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. We seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Systemic performance status 0-2 according to ECOG criteria
  • Patients with adequate renal function: serum Cr 1.4 mg/dL or less
  • Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal
  • Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)
  • Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)
  • Patients who voluntarily decided to participate in this study and signed a written informed consent form

排除标准

  • Patients undergoing immediate reconstruction operation
  • Patients with drug allergies to painkillers and anti-inflammatory drugs
  • Patients with a physical condition that would interfere with understanding and submitting the consent form

结局指标

主要结局

Postoperative hemovac or JP total drainage amount

时间窗: within 3 months

Postoperative hemovac or JP total drainage amount

Seroma incidence

时间窗: within 3 months

Seroma incidence

hematoma incidence

时间窗: within 3 months

hematoma incidence

次要结局

  • Length of hospital stay(within 3 months)
  • Complication(within 3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hyeong-Gon Moon

PF.

Seoul National University Hospital

相似试验

Seroma and Hematoma Rates: MAXIGESIC IV vs.... | 临床试验